<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-OIN-16008401</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2016-05-01</date_registration>
      <primary_sponsor>Institute of Hematology Blood Disease Hospital, Chinese Academy of Medical Sciences Peking Union Medical College </primary_sponsor>
      <public_title>The comparison of autologous stem cell transplantation vs. conventional chemotherapy in newly diagnosed high risk lymphoplasmacytic lymphoma / Waldenstrom macroglobulinemia </public_title>
      <acronym />
      <scientific_title>The comparison of autologous stem cell transplantation vs. conventional chemotherapy in newly diagnosed high risk lymphoplasmacytic lymphoma / Waldenstrom macroglobulinemia </scientific_title>
      <Scientific_acronym />
      <date_enrolment>2016-05-01</date_enrolment>
      <type_enrolment />
      <target_size>1:33;2:33;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=14224</url>
      <study_type>Observational study</study_type>
      <study_design>Non randomized control</study_design>
      <phase>III (Phase III study)</phase>
      <hc_freetext>lymphoplasmacytic lymphoma / Waldenstrom macroglobulinemia</hc_freetext>
      <i_freetext>1:autologous stem cell transplatation;2:conventional chemotherapy;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Shuhua Yi</firstname>
        <middlename />
        <lastname />
        <address>288 Nanjing Road, Heping District, Tianjin</address>
        <city />
        <country1 />
        <zip>300020</zip>
        <telephone>+86 15900265415</telephone>
        <email>shuhuayilove@163.com</email>
        <affiliation>Institute of Hematology Blood Disease Hospital, Chinese Academy of Medical Sciences Peking Union Medical College </affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Shuhua Yi</firstname>
        <middlename />
        <lastname />
        <address>288 Nanjing Road, Heping District, Tianjin</address>
        <city />
        <country1 />
        <zip>300020</zip>
        <telephone>+86 15900265415</telephone>
        <email>shuhuayilove@163.com</email>
        <affiliation>Institute of Hematology Blood Disease Hospital, Chinese Academy of Medical Sciences Peking Union Medical College </affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Aged &gt;=18 years;
2. diagnosed with high-risk LPL/WM according to the ISSWM criteria;
3. Untreated or mild treated without standard regimens;
4. suitable for ASCT;
5. with life-expectary more than 3 months.</inclusion_criteria>
      <agemin>18</agemin>
      <agemax>70</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. diagnosed with other malignancies outside B-NHL within one year(including active centre neural system lymphoma);
2. Transformed lymphoma;
3. liver or renal funcation lesion unrelated to lymphoma;
4. serious complications such as uncontroled diabetes, gastric ulcer or other serious angiocardiopathy determined by the physician;
5. HIV positive or active HBV infection or other uncontroled systematic infection;
6. clincial central nervous dysfunction;
7. serious surgery within 30 days;
8. pregnancy or baby nursing period or uncontracept child-bearing period woman;
9. allergy to the trail drugs.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>progression-free survival;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>overall survival;complete remission rate;duration of remission interval;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>State Science Technology Project from China</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2016-04-05</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>